

REMARKS

Pending claims

Claim 8 is canceled and claims 1, 5, and 28 have been amended to more clearly point out and distinctly claim the invention. The amendments is fully supported by the specification. For example, support for the phrase "wherein the radiation-curable (meth)acrylamidoalkyl derivative is added in the ink in an amount sufficient to provide the ink a desired viscosity for ink-jet printing or pad-printing while still being able to hold together and properly bind the ink to an ophthalmic lens onto which the ink is applied" can be found from the first paragraph on page 11 to the second paragraph on page 13; support for "ink binders" can be found on page 12, third full paragraph and page 13, the first and third full paragraphs. Thirteen (13) Claims (claims 1-7 and 26-31) are pending.

Rejections Under 35 USC 102

Claims 1-8 and 26-31 were rejected under 35 USC 102(b) as being anticipated by Symes et al. (USPN 4,778,880). The rejection over claim 8 is moot in view of its cancellation. The Examiner's rejection over claims 1-7 and 26-31 is also moot in view of the amendments of claims 1, 5 and 28. In particular, the cited reference does not disclose nor suggest anything about an ink comprising a binder mixture of an acrylate-modified poly(vinyl alcohol) and a radiation-curable (meth)acrylamidoalkyl derivative of an oligomer or polymer containing a plurality of H-active groups, anything about the addition of the radiation-curable (meth)acrylamidoalkyl derivative in the ink in an amount sufficient to provide the ink a desired viscosity for ink-jet printing or pad-printing while still being able to hold together and properly bind the ink to an ophthalmic lens onto which the ink is applied. Therefore, the cited reference does not disclose or teach all of the limitations of the invention as currently claimed. Applicants respectfully request withdrawal of this rejection.

CONCLUSION

In view of the foregoing and in conclusion, the Applicant submit that the rejections set-forth in the Office Action have been overcome, and that all pending claims are now in condition for allowance.

Should the Examiner believe that a discussion with Applicants' representative would further the prosecution of this application, the Examiner is respectfully invited to contact the undersigned. The Commissioner is hereby authorized to charge any other fees which may be required under 37 C.F.R. §§1.16 and 1.17, or credit any overpayment, to Deposit Account No. 50-2965.

Respectfully submitted,



Jian S. Zhou
Reg. No. 41,422
(678) 415-4691

Date: Jan 17, 2007

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080